🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

.Stephanie Bogan electrifying #AEDrive25 in her signature yellow jacket 💛delivering powerful insights on growth. Being a good person and working hard from your office isn’t enough anymore-firms must optimize for growth. “Growth isn’t magic, it’s a system.” AdvisorEngine

72% of financial advisory firms are hitting the ceiling of capacity and complexity says Stephanie Bogan We need to stop, reflect, and make the necessary changes to improve our situation in the first place. AdvisorEngine #AEDrive25 #Organicgrowth

The Changing Landscape of Advisor Marketing by my good friend and marketing expert Tina Powell of intention.ly at AdvisorEngine >Drive

“Sometimes change opens your eyes to who you’re becoming.” Amy DeTolla Founder of Aureus Advantage at #AEDrive25 on the invisible losses we resist—and why that’s exactly where the real work begins. AdvisorEngine #Leadership #ChangeManagement

Monday is coming! Listen to Amy DeTolla Founder of Aureus Advantage #AEDrive25 and take her advice AdvisorEngine

Thank you to AdvisorEngine for their invitation to speak at #AEDrive25 and treating me like real celeb 🙌 I loved every minute of it!

Thank you Gary Vaynerchuk VeeFriends | Fanatics Fest Booth 2319 great to see you today at GameStop I absolutely love my 🐯TREMENDOUS TIGER 🐯 you’re a beautiful human being ❤️

THANK YOU Gary Vaynerchuk XOXOXO

So much to celebrate and be grateful for AdvisorEngine ❤️ thank you again for the invitation to speak and be part of this awesomeness #AEDrive25

Don’t miss this opportunity to see Gary Vaynerchuk VeeFriends ❤️🐯❤️

#NewProfilePic

FDA grants accelerated approval to telisotuzumab vedotin (Teliso-V) for previously treated advanced NSCLC with c-MET overexpression. Teliso-V is an antibody drug conjugate (ADC) targeting MET; in the phase II LUMINOSITY trial, RR 35%, DOR 7.2m . onclive.com/view/fda-grant…

ToxCheck series: Common anti-EGFR drugs we use for mEGFR non-small cell #LungCancer w/ gilberto lopes ✅ Afatinib ✅ Osimertinib ✅ Amivantamab + Lazertinib Full discussion: ⭐️ oncbrothers.com/egfr-toxcheck-… ⭐️ Also on the “Oncology Brothers” podcast #lcsm #OncTwitter OncUpdates

What’s next for lung cancer treatment? At #ASCO25, Bruna Pellini, MD, (Bruna Pellini, MD) and Patrick Hwu, MD, (Dr. Patrick Hwu), Moffitt’s President and CEO, shared insights on promising lung cancer research and how it’s driving new hope for patients and progress in the field.

LinkedIn’s new playbook taps creators as the future of B2B marketing searchengineland.com/linkedin-playb…

So much fun recording this educational video with Jacob sands Dana-Farber and elaine shum NYU Langone Health on Evaluating #DatoDXd for #EGFR-Mutated Advanced NSCLC: Data from a Pooled Analysis reachmd.com/programs/front… via ReachMD EGFR Resisters

Before and After. Just 8 weeks. Nope, not lymphoma. THIS is non-small cell lung cancer. THIS is why molecular profiling matters. THIS is why targeted therapy changes lives.

Want to get one - are I collecting the card and comics but don’t know how to buy an nft ? We will hand hold u and help u veefriends.com/forms/my-first…

You often have to do something you don't like in order to have something you do.

Reenactment and reading of the Declaration of Independence 🇺🇸 Happy 4th everybody!